Abstract

The pres nt invention relates to selective binding partners for 5-HT5 receptors, processes for the identification and characterization of binding partners of this type, in particular in the form of screening processes, and also pharmaceutical compositions which contain these binding partners, and their use for the treatment of cerebrovascular disorders such as migraine.